List of Healthcare Family Offices

Key Facts About Healthcare Family Offices

• At least 79 family offices actively invest in healthcare services, collectively linked to 468 portfolio companies and 1,193 M&A deals.
• The vast majority operate as single family offices (SFOs), with multi-family offices (MFOs) like Interplay Family Office being rare exceptions.
• Health technology attracts 86% of family offices globally, making healthcare one of the most popular sectors for direct capital deployment.
• New York leads as the top geographic hub with 80+ SFOs, followed by Boston, San Francisco, and Newport Beach.
• Assets under management among profiled offices range from $2 billion (Tarsadia Investments) to over $90 billion (Mousse Partners), though most offices do not publicly disclose figures.
• Capital is flowing into digital health platforms, precision medicine, biotech drugs, and AI-driven drug discovery at venture and growth stages.

Market Landscape and Geographic Hubs

Healthcare family offices are SFOs and MFOs that allocate meaningful capital to biotech, medtech, digital health, pharma, and healthcare services. At least 79 such offices are tracked in healthcare services alone. Broader databases covering 4,000+ family offices worldwide rank healthcare as a top-tier allocation category, driven by high profit margins and long-term demographic tailwinds.

New York dominates with 80+ SFOs and 123 billionaires holding over $100 million in personal wealth. Boston anchors a biotech-focused cluster with offices like Raptor Group and Schooner Capital. San Francisco and Palo Alto attract tech-healthcare crossover investors such as Dolby Family Ventures and Baruch Future Ventures. Mumbai is emerging as a hub for health-tech venture investing, led by 4Point0.

Most offices in this niche are SFOs with deep sector conviction and flexible check sizes ranging from $300,000 to $200 million per deal. MFOs remain uncommon here; Interplay Family Office is one of the few offering full-service wealth management alongside healthcare deal access, with a $25 million minimum. Growth is fueled by aging populations, post-COVID digital health adoption, and strategic pharma buyers entering family office deal flow.

Side-by-Side Comparison of Leading Offices

The table below compares leading family offices investing in healthcare by type, disclosed AUM, sector focus, and representative deals.

Family Office	Type	AUM Estimate	Healthcare Focus	Notable Investments	Location
Cox Enterprises	SFO	$20B (revenue)	Mental health, value-based care	Motivo Health ($14M), Enlace Health ($58M)	Atlanta, GA
Duquesne Family Office	SFO	$12B+	Surgical robotics, radiotherapeutics	PROCEPT BioRobotics ($85M), Ratio Therapeutics ($20M)	New York, NY
Tarsadia Investments	SFO	$2B	Biotech, oncology, multi-stage	Asana Biosciences (oncology R&D)	Newport Beach, CA
Interplay Family Office	MFO	Not disclosed	Fertility, addiction treatment	Ophelia ($50M), Fertilidad Integral ($3.5M)	New York, NY
4Point0	SFO	Not disclosed	Health-tech startups (Asia)	Fitterfly ($12M), Saveo ($4.5M)	Mumbai, India
Dolby Family Ventures	SFO	Not disclosed	Brain-computer interfaces, life sciences	Paradromics ($33M), Genemod ($4.5M)	San Francisco, CA
Willet Advisors	SFO	Not disclosed	Therapeutics (oncology, neuro)	Scorpion, Carmot, Neurona Therapeutics	New York, NY
Raptor Group	SFO	Not disclosed	Biotech, non-invasive diagnostics	Genetesis (cardiac mapping)	Boston, MA
Schooner Capital	SFO	Not disclosed	Cancer therapeutics, growth equity	Remedy Plan Therapeutics, SRS Medical	Boston, MA
Pritzker Vlock Family Office	SFO	Not disclosed	Biotech, medical devices	Gelesis (obesity/diabetes smart pill)	New Haven, CT
Junson Capital	SFO	$7.8B (net worth)	Biotech, robotics	WiBiotic (wireless power)	Hong Kong
Baruch Future Ventures	SFO	Not disclosed	Microbiome, phage therapies	BiomX (IBD, colorectal cancer)	San Francisco, CA

AUM data remains scarce in this niche. Only three offices on this list publicly disclose assets, reflecting the private nature of SFO capital. Offices without disclosed AUM should not be assumed smaller. Willet Advisors manages Michael Bloomberg's personal fortune, and the Pritzker family ranks among the wealthiest in the U.S.

Top Picks by Strategy

• Largest Healthcare Portfolio: Cox Enterprises, with $20 billion in annual revenue and allocations spanning Motivo Health ($14M Series A) and Enlace Health ($58M) in value-based care.
• Leading Surgical and Biotech Investor: Duquesne Family Office, Stanley Druckenmiller's $12B+ SFO that backed PROCEPT BioRobotics' $85M Series G for autonomous surgical robots.
• Best for Multi-Stage Flexibility: Tarsadia Investments writes checks from $5M to $200M per deal, covering venture through buyout in healthcare and biotech.
• Strongest MFO Platform: Interplay Family Office, offering estate planning, tax management, and charitable support alongside healthcare deal flow with a $25M minimum.
• Most Focused Health-Tech Investor: 4Point0 exclusively targets venture-stage health-tech startups, with observed deal sizes of $4.5M to $12M in Asia.
• Top Neuroscience and Frontier Play: Dolby Family Ventures co-invested $33M in Paradromics' brain-computer interface and $4.5M in Genemod's life sciences cloud platform.
• Healthcare Operator Turned Investor: Northwoods Partners, built in 2022 from the ImageFIRST healthcare linen business, now actively sources M&A deals with three closed transactions.

Detailed Office Profiles

Cox Enterprises

Few offices investing in healthcare can match the operational scale of Cox Enterprises. The Atlanta-based SFO behind a $20 billion revenue conglomerate with 50,000+ employees allocates venture and growth capital to clinical supervision and health data analytics. Its $14 million Series A lead in Motivo Health targets affordable therapist supervision. A $58 million commitment to Enlace Health funds the shift from fee-for-service to value-based care.

Healthcare founders seeking a lead investor with corporate distribution channels and co-investment appetite will find Cox among the most active SFOs in this space. The office invests at multiple stages and has shown willingness to anchor rounds.

Duquesne Family Office

Stanley Druckenmiller converted his hedge fund into this SFO in 2010, carrying over $12 billion in assets at closure. The office has since built a concentrated portfolio focused on surgical robotics and targeted cancer treatment.

Its $85 million Series G backing of PROCEPT BioRobotics funded the world's first autonomous surgical robots for benign prostatic hyperplasia. A $20 million Series A in Ratio Therapeutics supports targeted radiotherapeutics for oncology. Check sizes of $20M to $85M signal a preference for later-stage companies with clinical validation, making Duquesne a strong fit for biotech firms past proof-of-concept.

Tarsadia Investments

Tarsadia is one of the few healthcare SFOs that publicly reports its capital base: $2 billion in disclosed family assets. The Newport Beach office invests from $5 million to $200 million per deal. It covers majority and minority stakes in private companies, public equity, and early-stage ventures.

Its healthcare portfolio includes Asana Biosciences, a research company focused on oncology, pain, and inflammation drug candidates. That multi-stage flexibility sets Tarsadia apart from offices locked into a single check size. Biotech founders at any stage can approach Tarsadia if their capital needs fall within the $5M to $200M range.

Interplay Family Office

Interplay is the only multi-family office on this list, operating as a registered investment advisor in New York with a $25 million minimum relationship size. It offers a complete suite of wealth management services: asset allocation, estate planning, tax management, reporting, and charitable support.

On the deal side, Interplay participated in Ophelia's $50 million Series B for online opioid addiction treatment (now in 27 states) and a $3.5 million venture round for Fertilidad Integral in Mexico. Ultra-high-net-worth (UHNW) families wanting healthcare exposure plus broad wealth management under one roof have few alternatives in this niche.

4Point0

Nihar Parikh's Mumbai-based SFO invests only in venture-stage health-tech startups. Parikh, whose family built Zandu Pharmaceuticals, launched 4Point0 in 2022 to back companies where the office's strategic input creates direct value.

A $12 million allocation to Fitterfly supports digital therapy for diabetes and weight management. A $4.5 million round in Saveo funds a B2B pharma marketplace aiming to improve drug access in India. The office favors Asia-based ventures, making it a strong match for health-tech founders in India and the surrounding region.

Dolby Family Ventures

Built on the Dolby Laboratories fortune, this San Francisco SFO invests exclusively through co-investments alongside other funds. It writes checks of $300,000 to $3 million. Its healthcare portfolio targets frontier neuroscience and life sciences tools.

A $33 million co-investment in Paradromics funds a brain-computer interface for patients with severe paralysis. A $4.5 million seed round in Genemod backs a cloud platform for life sciences data. For early-stage companies already raising a round with a lead investor, Dolby offers patient capital, business expertise, and industry networking.

Willet Advisors

Michael Bloomberg's personal wealth platform has pivoted recently toward concentrated bets in therapeutics. Willet Advisors backs Scorpion Therapeutics (oncology), Carmot Therapeutics (metabolic disease), and Neurona Therapeutics (cell therapy for neurological conditions).

The New York SFO also manages Bloomberg's charitable capital and multi-asset portfolio. While check sizes are not publicly disclosed, ties to Bloomberg's $100 billion+ fortune suggest meaningful capacity. Therapeutics companies with strong clinical pipelines represent the clearest fit for Willet's current strategy.

Raptor Group

Jim Palotta, former Vice Chairman at Tudor Investment Corporation and Boston Celtics owner, runs this Boston SFO with healthcare and biotech as a core pillar. Raptor Group targets early and seed-stage capital deployment.

Its portfolio includes Genetesis, a medical technology company developing non-invasive cardiac current density mapping. This system generates images of the heart's electrical distribution. Boston's dense biotech ecosystem gives Raptor strong deal sourcing in diagnostics and life sciences. The office also invests in technology, consumer, sports, and media, giving portfolio companies potential cross-sector synergies.

Schooner Capital

The Vin Ryan family's SFO ranks among the longest-running private wealth offices on this list, with over five decades of investing since 1971. Schooner Capital focuses on venture capital, growth equity, and public securities with healthcare and biotech as key verticals.

Its portfolio includes Remedy Plan Therapeutics, which develops small-molecule drugs to halt tumor growth and disrupt cancer stem cells, and SRS Medical Systems for urological conditions. That long track record in private markets appeals to healthcare founders seeking investors with deep patience and succession planning expertise built into their own family governance structure.

Pritzker Vlock Family Office

The Pritzker family's Hyatt Hotels fortune places them consistently on Forbes' wealthiest families list. This SFO operates from New Haven, Connecticut. Pritzker Vlock manages a global asset base including emerging biotech and medical device companies.

A standout allocation is Gelesis, a clinical-stage biotech developing a hydrogel smart pill for obesity and diabetes. The pill expands to 100 times its dry weight in the stomach. Biotech founders working on clinical-stage devices or therapeutics for metabolic disease will find alignment with this office's thesis.

Where Private Wealth Is Flowing in Healthcare

Digital Health and AI-Driven Drug Discovery

An estimated 86% of family offices invest in health technology. Healthcare-focused SFOs are concentrating capital in digital therapeutics and AI-powered platforms. 4Point0's $12 million bet on Fitterfly targets digital therapy for diabetes. Dolby Family Ventures' $4.5 million seed in Genemod funds cloud tools for life sciences research.

AI-driven drug discovery is pulling early-stage capital into pre-clinical companies where traditional venture funds may lack the patience for long development timelines. This trend is especially visible among single family offices with biotech operating backgrounds, like 4Point0 and Baruch Future Ventures.

Direct Capital Replacing Fund Allocations

Offices in this sector increasingly bypass fund-of-funds structures to invest directly in companies. Northwoods Partners has closed three M&A deals since 2022. Iron Creek Partners has completed 14 total buyout transactions in healthcare technology and software.

This shift gives family offices more control over deal selection, lower fee drag, and deeper portfolio company relationships. It also demands in-house healthcare expertise that only sector-focused offices can maintain, creating a competitive moat for the specialists profiled here.

Precision Medicine and Targeted Therapeutics

Duquesne's $20 million in Ratio Therapeutics and Willet Advisors' backing of Scorpion Therapeutics reflect growing appetite for precision oncology. Schooner Capital's allocation to Remedy Plan Therapeutics targets cancer stem cells with small-molecule drugs.

These deals require longer hold periods and higher risk tolerance than digital health bets. Yet the potential for outsized returns from successful drug approvals attracts family offices with patient, long-term capital, especially SFOs without fund lifecycle constraints.

Impact-Focused Capital in Accessible Healthcare

A growing subset of offices in this niche prioritizes access and affordability alongside returns. Cox Enterprises' backing of Motivo Health ($14 million) aims to reduce the cost of therapist supervision nationally. 4Point0's allocation to Saveo targets drug access gaps in India.

Industry events now regularly connect private wealth managers to healthcare companies focused on underserved populations, including Dala.Care and Mahzi Therapeutics. This trend reflects broader demand for purposeful capital deployment among next-generation family members.

Choosing the Right Office in This Niche

Healthcare expertise matters more than general wealth management credentials when selecting an office in this sector. A generalist firm may offer strong estate planning, but healthcare allocations require knowledge of FDA timelines, reimbursement models, and clinical trial economics. Duquesne and Tarsadia demonstrate this through concentrated biotech portfolios. Cox Enterprises shows it through operational healthcare capital deployment.

Check size alignment is the first filter. Deal sizes in this niche range from $300,000 (Dolby Family Ventures co-investments) to $200 million (Tarsadia majority stakes). A mismatch between your capital needs and an office's typical check size wastes time for both sides. Ask for the office's range and recent deal sizes before pitching.

Stage preference eliminates further. 4Point0 only backs venture-stage startups; approaching them with a growth equity deal will not work. Northwoods Partners focuses on M&A buyouts. Schooner Capital spans venture through public securities. Match your company's maturity to the office's preferred stage before outreach.

Geographic focus narrows the field further. 4Point0 favors Asia-based health-tech ventures. Raptor Group and Schooner Capital draw deal flow from Boston's biotech corridor. Cox Enterprises invests nationally but is headquartered in Atlanta. Junson Capital in Hong Kong invests globally, but proximity to an office's home market can improve deal sourcing.

Service breadth separates SFOs from MFOs in practical terms. UHNW families wanting tax management, estate planning, and healthcare deal access simultaneously should evaluate Interplay's full-service MFO model. Families focused solely on deal access may prefer a lean SFO with deeper sector conviction.

Which Office Fits Your Needs?

UHNW families seeking full-service wealth management alongside healthcare exposure should explore Interplay, the only MFO on this list with a dedicated healthcare allocation and services spanning estate planning, tax, and charitable support. Tarsadia also suits families wanting diversified healthcare exposure through a single relationship, given its $5M to $200M deal range and multi-stage flexibility.

Healthcare founders raising venture rounds should focus on 4Point0 for health-tech in Asia, Dolby Family Ventures for co-investments in neuroscience and life sciences tools, or Raptor Group for early-stage biotech in the Boston corridor. Each office brings sector knowledge and networks that generic venture capital cannot replicate. Founders past proof-of-concept with larger capital needs can approach Duquesne or Cox Enterprises, both of which have written checks above $50 million in recent healthcare rounds.

Next-generation wealth holders interested in impact-driven healthcare investing will find alignment with offices backing accessible care: Cox Enterprises (Motivo Health), 4Point0 (Fitterfly, Saveo), and Baruch Future Ventures (BiomX). These offices combine return expectations with measurable health outcomes. This approach matches growing demand for purposeful capital among younger family members managing succession planning and governance transitions.

Methodology

This list of healthcare family offices was compiled from public records, deal databases tracking 79+ investors in this sector, and verified portfolio company data as of 2026. Offices were selected based on documented healthcare allocations, disclosed deal activity, and sector focus. AUM figures are included only where publicly reported or confirmed through fund closure records. Offices without disclosed managed assets were not excluded, as most SFOs in this niche operate privately. Deal amounts reflect the total round size where the office participated, not necessarily the office's individual commitment. Geographic, stage, and sector classifications are based on each office's stated mandate and observed portfolio activity.